Antifibrinolytic agents in subarachnoid haemorrhage.
For many years clinicians have used antifibrinolytic agents to try to reduce rebleeding after subarachnoid haemorrhage. Early studies of their effectiveness produced conflicting results. This paper re-evaluates the available trials and considers benefits in the light of potential complications. Present evidence conclusively demonstrates that epsilon-aminocaproic acid and tranexamic acid administered in standard dosage, reduce the risk of rebleeding but, as a result of an increased incidence of ischaemic complications, do not benefit patients' outcome.
D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy*
D000933:Antifibrinolytic Agents